Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14554603 | 0.92 | MAPT (0.43) | MAPTSMN1; SMN2CNR2 | |
| SCHEMBL14554498 | 0.91 | MAPT (0.45) | MAPTSMN1; SMN2CNR2CLCN2 | |
| SCHEMBL14488370 | 0.87 | CSF1R (0.40) | — | |
| SCHEMBL14488779 | 0.86 | NUDT1 (0.38) | MAPTSMN1; SMN2CNR2 | |
| SCHEMBL14488511 | 0.85 | SIRT5 (0.38) | MAPT | |
| SCHEMBL14488437 | 0.85 | DHODH (0.45) | MAPT | |
| SCHEMBL14554791 | 0.85 | CLCN2 (0.40) | MAPTSMN1; SMN2CLCN2 | |
| SCHEMBL14486263 | 0.84 | MAPK1 (0.39) | MAPTSMN1; SMN2CNR2 | |
| SCHEMBL14488539 | 0.83 | AURKA (0.48) | MAPTSMN1; SMN2 | |
| SCHEMBL14485995 | 0.83 | CSF1R (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006442-B2 | Cannabinoid receptor modulators | LUPIN LIMITED (IN) | 2015-04-14 | — | — | US | claimed |
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | claimed |
| WO-2013005168-A2 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-01-10 | — | — | WO | claimed |
| US-9006442-B2 | Cannabinoid receptor modulators | LUPIN LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-9006442-B2 | Cannabinoid receptor modulators | LUPIN LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-9006442-B2 | Cannabinoid receptor modulators | LUPIN LIMITED (IN) | 2015-04-14 | — | — | US | disclosed |
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | disclosed |
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | disclosed |
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | disclosed |
| WO-2013005168-A2 | CANNABINOID RECEPTOR MODULATORS | LUPIN LIMITED (IN) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178457-A1 | CANNABINOID RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | MAPT 2605/4885SMN1; SMN2 1740/4885CNR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.